It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Assessment of tumor-infiltrating lymphocytes (TILs) is increasingly recognized as an integral part of the prognostic workflow in triple-negative (TNBC) and HER2-positive breast cancer, as well as many other solid tumors. This recognition has come about thanks to standardized visual reporting guidelines, which helped to reduce inter-reader variability. Now, there are ripe opportunities to employ computational methods that extract spatio-morphologic predictive features, enabling computer-aided diagnostics. We detail the benefits of computational TILs assessment, the readiness of TILs scoring for computational assessment, and outline considerations for overcoming key barriers to clinical translation in this arena. Specifically, we discuss: 1. ensuring computational workflows closely capture visual guidelines and standards; 2. challenges and thoughts standards for assessment of algorithms including training, preanalytical, analytical, and clinical validation; 3. perspectives on how to realize the potential of machine learning models and to overcome the perceptual and practical limits of visual scoring.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



















1 Emory University School of Medicine, Department of Biomedical Informatics, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
2 University of Copenhagen, Department of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
3 Technical University of Denmark, DTU Compute, Department of Applied Mathematics, Lyngby, Denmark (GRID:grid.5170.3) (ISNI:0000 0001 2181 8870); Visiopharm A/S, Hørsholm, Denmark (GRID:grid.5170.3)
4 FDA/CDRH/OSEL/Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, USA (GRID:grid.5170.3)
5 PathAI, Cambridge, USA (GRID:grid.479429.5)
6 Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Philipps-Universität Marburg, Institut für Pathologie, Marburg, Germany (GRID:grid.10253.35) (ISNI:0000 0004 1936 9756); Institute of Pathology, Philipps-University Marburg, Marburg, Germany (GRID:grid.10253.35) (ISNI:0000 0004 1936 9756); German Cancer Consortium (DKTK), Partner Site Charité, Berlin, Germany (GRID:grid.10253.35)
7 The Institute of Cancer Research, Centre for Evolution and Cancer, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623); The Institute of Cancer Research, Division of Molecular Pathology, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623)
8 Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Philipps-Universität Marburg, Institut für Pathologie, Marburg, Germany (GRID:grid.10253.35) (ISNI:0000 0004 1936 9756)
9 University of Melbourne, Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Victoria, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); University of Melbourne, Sir Peter MacCallum Department of Oncology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
10 The Netherlands Cancer Institute, Department of Tumor Biology & Immunology, Amsterdam, The Netherlands (GRID:grid.430814.a)
11 Case Western Reserve University, Department of Biomedical Engineering, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, USA (GRID:grid.410349.b) (ISNI:0000 0004 0420 190X)
12 Karolinska Institutet and University Hospital, Department of Oncology and Pathology, Solna, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
13 The University of Texas MD Anderson Cancer Center, Departments of Epigenetics and Molecular Carcinogenesis, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
14 The Netherlands Cancer Institute, Division of Molecular Pathology, Amsterdam, The Netherlands (GRID:grid.430814.a)
15 The Netherlands Cancer Institute, Department of Research IT, Amsterdam, The Netherlands (GRID:grid.430814.a)
16 Radboud University Medical Center, Department of Pathology, Nijmegen, The Netherlands (GRID:grid.10417.33) (ISNI:0000 0004 0444 9382)
17 UCL Cancer Institute, Department of Pathology, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
18 Icahn School of Medicine at Mount Sinai, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)
19 Université Paris-Saclay, Univ. Paris-Sud, Villejuif, France (GRID:grid.5842.b) (ISNI:0000 0001 2171 2558)
20 University of São Paulo, Department of Pathology, Faculty of Medicine, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
21 Gustave Roussy Cancer Campus, Department of Medical Biology and Pathology, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
22 Massachusetts General Hospital, Department of Pathology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
23 Manipal Hospitals Dwarka, Department of Histopathology, New Delhi, India (GRID:grid.32224.35)
24 National Taiwan University Cancer Center, Department of Oncology, Taipei, Taiwan (GRID:grid.19188.39) (ISNI:0000 0004 0546 0241)
25 University of Oxford, Nuffield Department of Population Health, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University Hospitals Bristol NHS Foundation Trust, Department of Medical Oncology, Bristol, UK (GRID:grid.410421.2) (ISNI:0000 0004 0380 7336)
26 Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, School of Medicine, Pathology Department, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)
27 Weill Cornell Medical College, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
28 Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA (GRID:grid.240324.3) (ISNI:0000 0001 2109 4251)
29 Brigham and Women’s Hospital, Department of Pathology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
30 The University of Queensland Centre for Clinical Research and Pathology Queensland, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
31 CIBERONC-Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Pathology Department, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126); GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain (GRID:grid.430580.a)
32 Indiana University School of Medicine, Department of Pathology and Laboratory Medicine, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919)
33 Roche Tissue Diagnostics, Digital Pathology, Santa Clara, USA (GRID:grid.257413.6)
34 The University of Texas MD Anderson Cancer Center, Department of Pathology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
35 Université Libre de Bruxelles (ULB), Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746); ULB-Cancer Research Center (U-CRC) Université Libre de Bruxelles, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)
36 Vanderbilt University Medical Center, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
37 NRG Oncology/NSABP, Pittsburgh, USA (GRID:grid.412807.8)
38 Yale University School of Medicine, Department of Pathology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
39 IEO, European Institute of Oncology IRCCS & State University of Milan, Department of Pathology, Milan, Italy (GRID:grid.15667.33) (ISNI:0000 0004 1757 0843)
40 National Cancer Institute, National Institutes of Health, Laboratory of Pathology, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
41 Ontario Institute for Cancer Research, Toronto, Canada (GRID:grid.419890.d) (ISNI:0000 0004 0626 690X); Western General Hospital, Edinburgh Cancer Research Centre, Edinburgh, UK (GRID:grid.417068.c) (ISNI:0000 0004 0624 9907)
42 Centre Jean Perrin, Department of Pathology and Molecular Pathology, Clermont-Ferrand, France (GRID:grid.418113.e) (ISNI:0000 0004 1795 1689); Universite Clermont Auvergne, UMR INSERM 1240, Clermont-Ferrand, France (GRID:grid.494717.8) (ISNI:0000000115480420)
43 Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre building, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
44 National Taiwan University Hospital, Department of Pathology, Taipei, Taiwan (GRID:grid.412094.a) (ISNI:0000 0004 0572 7815)
45 German Breast Group, c/o GBG-Forschungs GmbH, Neu-Isenburg, Germany (GRID:grid.434440.3) (ISNI:0000 0004 0457 2954)
46 BC Cancer, Department of Pathology, Vancouver, Canada (GRID:grid.434440.3)
47 University of Melbourne, Sir Peter MacCallum Department of Oncology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
48 Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
49 Universite Paris-Saclay, Gustave Roussy, Villejuif, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535); Université Paris-Sud, Institut National de la Santé et de la Recherche Médicale, Villejuif, France (GRID:grid.5842.b) (ISNI:0000 0001 2171 2558)
50 The Netherlands Cancer Institute, Division of Molecular Oncology & Immunology, Amsterdam, The Netherlands (GRID:grid.430814.a); The Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, The Netherlands (GRID:grid.430814.a)
51 University of British Columbia, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
52 The University of Texas MD Anderson Cancer Center, Department of Pathology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); The University of Texas MD Anderson Cancer Center, Department of Genomic Medicine, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); The University of Texas MD Anderson Cancer Center, Department of Translational Molecular Pathology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); The University of Texas MD Anderson Cancer Center, Department of Dermatology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
53 Medical University of Vienna, Department of Pathology, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
54 Maastricht University Medical Centre, GROW - School for Oncology and Developmental Biology, Maastricht, The Netherlands (GRID:grid.412966.e) (ISNI:0000 0004 0480 1382); Maastricht University Medical Centre, Department of Pathology, Maastricht, The Netherlands (GRID:grid.412966.e) (ISNI:0000 0004 0480 1382)
55 Radboud University Medical Center, Department of Pathology, Nijmegen, The Netherlands (GRID:grid.10417.33) (ISNI:0000 0004 0444 9382); Linköping University, Center for Medical Image Science and Visualization, Linköping, Sweden (GRID:grid.5640.7) (ISNI:0000 0001 2162 9922)
56 Stony Brook University, Department of Biomedical Informatics, Stony Brook, USA (GRID:grid.36425.36) (ISNI:0000 0001 2216 9681)
57 FDA/CDRH/OSEL/Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, USA (GRID:grid.36425.36)
58 Roche Tissue Diagnostics, Digital Pathology, Santa Clara, USA (GRID:grid.36425.36)
59 Roche Diagnostics Information Solutions, Belmont, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718)
60 University of Melbourne, Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Victoria, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); GZA-ZNA Ziekenhuizen, Department of Pathology, Antwerp, Belgium (GRID:grid.428965.4) (ISNI:0000 0004 7536 2436)
61 Northwestern University Feinberg School of Medicine, Department of Pathology, Chicago, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
62 Department of Oral and Maxillofacial Diseases, Helsinki, Finland (GRID:grid.16753.36)
63 Matsuyama Shimin Hospital, Department of Pathology, Matsuyama, Japan (GRID:grid.459780.7) (ISNI:0000 0004 1772 4320)
64 Baylor College of Medicine, Surgical Oncology, Texas, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)
65 Roche Diagnostics, Machelen, Belgium (GRID:grid.39382.33)
66 PhenoPath Laboratories, Seattle, USA (GRID:grid.39382.33)
67 Genentech Inc., Research Pathology, South San Francisco, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718)
68 University of Turin, Italy and Candiolo Cancer Institute - FPO, IRCCS, Department of Medical Sciences, Candiolo, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580)
69 New York University, Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
70 Johns Hopkins Hospital, Department of Pathology, Baltimore, USA (GRID:grid.411935.b) (ISNI:0000 0001 2192 2723)
71 University of Milan, Department of Pathology, Istituto Europeo di Oncologia, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)
72 University of Iowa Hospitals and Clinics, Department of Pathology, Iowa City, USA (GRID:grid.412584.e) (ISNI:0000 0004 0434 9816)
73 The Institute of Cancer Research, Breast Cancer Now Toby Robins Research Centre, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623)
74 Instituto Valenciano de Oncología, Department of Oncology, Valencia, Spain (GRID:grid.418082.7) (ISNI:0000 0004 1771 144X)
75 Cancer Centre at Guy’s Hospital, Cancer Bioinformatics Lab, London, UK (GRID:grid.239826.4) (ISNI:0000 0004 0391 895X); King’s College London, School of Life Sciences and Medicine, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
76 Skåne University Hospital, Lund University, Department of Clinical Genetics and Pathology, Lund, Sweden (GRID:grid.13097.3c)
77 Dana-Farber Cancer Institute, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
78 Paris Sciences Lettres Université, Inserm U934, Department of Pathology, Institut Curie, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389)
79 Department of Surgical Pathology Zealand University Hospital, Køge, Denmark (GRID:grid.476266.7)
80 The Johns Hopkins Hospital, Departments of Pathology and Oncology, Baltimore, USA (GRID:grid.411935.b) (ISNI:0000 0001 2192 2723)
81 National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
82 Karolinska Institute, Department of Pathology, Solna, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
83 New York University Langone Medical Centre, Department of Pathology, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
84 UNC School of Medicine, Department of Pathology and Laboratory Medicine, Columbia, USA (GRID:grid.10698.36) (ISNI:0000000122483208)
85 Laval University, Québec Heart and Lung Institute Research Center, Quebec city, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390)
86 Peter MacCallum Cancer Centre, Department of Medical Oncology, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
87 University of Melbourne, Department of Medicine, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
88 British Columbia Cancer Agency, Trev & Joyce Deeley Research Centre, Victoria, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000)
89 Instituto Nacional de Enfermedades Neoplásicas, Department of Medical Oncology, Lima, Perú (GRID:grid.419177.d) (ISNI:0000 0004 0644 4024); Instituto Nacional de Enfermedades Neoplasicas, Department of Research, Lima, Peru (GRID:grid.419177.d) (ISNI:0000 0004 0644 4024)
90 Providence Cancer Research Center, Portland, Oregon, USA (GRID:grid.419177.d)
91 Department of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy (GRID:grid.15667.33) (ISNI:0000 0004 1757 0843)
92 Roche Diagnostics, Machelen, Belgium (GRID:grid.15667.33)
93 Department of Pathology, AZ Turnhout, Turnhout, Belgium (GRID:grid.476094.8)
94 St Vincent’s University Hospital and University College Dublin, Department of Pathology, Dublin, Ireland (GRID:grid.412751.4) (ISNI:0000 0001 0315 8143)
95 University of Pittsburgh, Department of Computational and Systems Biology, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
96 University College London Cancer Institute, University College London, Cancer Research UK Lung Cancer Centre of Excellence, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
97 Regional Hospital of Aosta, Azienda AUSL, Aosta, Italy (GRID:grid.83440.3b)
98 University Hospital Halle (Saale), Institute of Pathology, Halle, Germany (GRID:grid.461820.9) (ISNI:0000 0004 0390 1701)
99 Brigham and Women’s Hospital, Boston, MA Department of Pathology, Dana Farber Cancer Institute, Department of Pathology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
100 Jules Bordet Institute, Department of Pathology, Brussels, Belgium (GRID:grid.418119.4) (ISNI:0000 0001 0684 291X)
101 Macquarie University, Department of Clinical Medicine, Sydney, Australia (GRID:grid.1004.5) (ISNI:0000 0001 2158 5405)
102 HistoGeneX NV, Antwerp, Belgium and AZ Sint-Maarten Hospital, Mechelen, Belgium (GRID:grid.1004.5)
103 Bristol-Myers Squibb, Oncology Clinical Development, Princeton, USA (GRID:grid.419971.3)
104 Institut für Pathologie, UK Hamburg, Hamburg, Germany (GRID:grid.419971.3)
105 Vanderbilt University Medical Centre, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
106 Department of Cancer Biology, Mayo Clinic, Jacksonville, USA (GRID:grid.417467.7) (ISNI:0000 0004 0443 9942)
107 Department of Oncology, Mayo Clinic, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
108 Roche, Tucson, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718)
109 Universidad de La Frontera, Department of Pathology, Temuco, Chile (GRID:grid.412163.3) (ISNI:0000 0001 2287 9552); Universidad de La Frontera, Departamento de Anatomía Patológica, Temuco, Chile (GRID:grid.412163.3) (ISNI:0000 0001 2287 9552)
110 Maria Sklodowska-Curie Memorial Cancer Center, Tumor Pathology Department, Gliwice, Poland (GRID:grid.418165.f) (ISNI:0000 0004 0540 2543)
111 Pathology and Tissue Analytics, Roche, Machelen, Belgium (GRID:grid.476562.4)
112 Department of Medical Oncology, Gustave Roussy, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
113 Sunnybrook Health Sciences Centre, Toronto, Canada (GRID:grid.413104.3) (ISNI:0000 0000 9743 1587)
114 Tehran University of Medical Sciences, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)
115 Translational Research, Montreal, Canada (GRID:grid.411705.6)
116 Oncology Biomarker Development, Genentech-Roche, Machelen, Belgium (GRID:grid.411705.6)
117 Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X)
118 Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
119 Hospital de Oncología Maria Curie, Department of Pathology, Buenos Aires, Argentina (GRID:grid.6363.0)
120 Directorate of Surgical Pathology, SA Pathology, Adelaide, Australia (GRID:grid.414733.6) (ISNI:0000 0001 2294 430X)
121 GZA-ZNA Hospitals, Department of Pathology, Wilrijk, Belgium (GRID:grid.414733.6)
122 University of Milano, Istituto Europeo di Oncologia, IRCCS, Milano, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822); Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology IRCCS, Milan, Italy (GRID:grid.15667.33) (ISNI:0000 0004 1757 0843)
123 Laboratory of Translational Cell & Tissue Research, Department of Imaging and Pathology, Leuven, Belgium (GRID:grid.15667.33); KU Leuven- University Hospitals Leuven, Department of Pathology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
124 University Hospital Antwerp, Department of Pathology, Antwerp, Belgium (GRID:grid.411414.5) (ISNI:0000 0004 0626 3418)
125 Translational Health Sciences, Department of Cellular Pathology, North Bristol NHS Trust, University of Bristol, Bristol, UK (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603)
126 Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
127 Helsinki University Central Hospital, Helsinki, Finland (GRID:grid.15485.3d) (ISNI:0000 0000 9950 5666)
128 Akademiska University Hospital, Department of Clinical Pathology, Uppsala, Sweden (GRID:grid.412354.5) (ISNI:0000 0001 2351 3333)
129 International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France (GRID:grid.17703.32) (ISNI:0000000405980095)
130 Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (GRID:grid.430814.a)
131 Department of Pathology, Sanatorio Mater Dei, Buenos Aires, Argentina (GRID:grid.430814.a)
132 Institute of Pathology, Medical University of Graz, Graz, Austria (GRID:grid.11598.34) (ISNI:0000 0000 8988 2476)
133 National Cancer Centre, Department of Oncology, Singapore, Singapore (GRID:grid.410724.4) (ISNI:0000 0004 0620 9745)
134 Vivactiv Ltd, Bellingdon, Bucks, UK (GRID:grid.410724.4)
135 Netherlands Cancer Institute, Department of Pathology, Amsterdam, The Netherlands (GRID:grid.430814.a)
136 R&D UNICANCER, Paris, France (GRID:grid.418158.1)
137 Translational Sciences, MedImmune, Gaithersberg, USA (GRID:grid.418152.b)
138 Breast Unit, Champalimaud Clinical Centre, Lisboa, Portugal (GRID:grid.418152.b)
139 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
140 Clinical Division of Oncology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Department of Medicine, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
141 University of Leicester, Leicester, and MRC Toxicology Unit, University of Cambridge, Leicester Cancer Research Centre, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
142 Merck & Co., Inc, Kenilworth, USA (GRID:grid.417993.1) (ISNI:0000 0001 2260 0793)
143 Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952); Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
144 The Netherlands Cancer Institute, Department of Pathology, Amsterdam, The Netherlands (GRID:grid.430814.a)
145 Instituto Nacional de Enfermedades Neoplasicas, Department of Research, Lima, Peru (GRID:grid.419177.d) (ISNI:0000 0004 0644 4024)
146 Department of Medicine, Department of Obstetrics & Gynecology and Women’s Health, Albert Einstein Medical Center, Bronx, USA (GRID:grid.419177.d)
147 GHI Le Raincy-Montfermeil, Chelles, Île-de-France, France (GRID:grid.420138.c) (ISNI:0000 0000 8620 9964)
148 Universidad de La Frontera, Department of Pathology, Temuco, Chile (GRID:grid.412163.3) (ISNI:0000 0001 2287 9552)
149 Department of Pathology, Gustave Roussy, Grand Paris, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
150 Vanderbilt University Medical Centre, Departments of Medicine and Cancer Biology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
151 Vm Scope, Berlin, Germany (GRID:grid.412807.8)
152 Breast Pathology Section, Northwestern University, Department of Pathology, Chicago, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
153 Institut Jules Bordet, Université Libre de Bruxelles, Molecular Immunology Unit, Brussels, Belgium (GRID:grid.418119.4) (ISNI:0000 0001 0684 291X)
154 The Netherlands Cancer Institute, Department of Biometrics, Amsterdam, The Netherlands (GRID:grid.430814.a)
155 German Breast Group, Neu-Isenburg, Germany (GRID:grid.434440.3) (ISNI:0000 0004 0457 2954)
156 Université Mohamed Premier, Cancer Biomarkers Working Group, Faculty of Medicine and Pharmacy, Oujda, Morocco (GRID:grid.410890.4) (ISNI:0000 0004 1772 8348)
157 Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale School of Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
158 Stanford University Medical Centre, Pathology Department, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
159 University Hospital Ghent, Department of Pathology, Ghent, Belgium (GRID:grid.410566.0) (ISNI:0000 0004 0626 3303)
160 Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg, Germany (GRID:grid.410566.0)
161 Center for Pharmacogenomics and Fudan-Zhangjiang, Center for Clinical Genomics School of Life Sciences and Shanghai Cancer Center, Fudan University, Fudan, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443)
162 Sichuan Cancer Hospital, Chengdu, China (GRID:grid.415880.0) (ISNI:0000 0004 1755 2258)
163 Oncology Biomarker Development, Genentech-Roche, Machelen, Belgium (GRID:grid.415880.0)
164 University of California San Diego, Biorepository and Tissue Technology Shared Resources, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
165 Department of Pathology, Gustave Roussy, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
166 The Institute of Cancer Research, Institute of Cancer Research Clinical Trials and Statistics Unit, Surrey, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623)
167 Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands (GRID:grid.5650.6) (ISNI:0000000404654431)
168 University of Padova, Department of Surgery, Oncology and Gastroenterology, Padua, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
169 Universite Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)
170 Vanderbilt University Medical Centre, Department of Pathology, Microbiology and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
171 Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Division of Biostatistics, Dana-Farber Cancer Institute, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
172 Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville, Australia (GRID:grid.416153.4) (ISNI:0000 0004 0624 1200)
173 Vernon Cancer Center, Newton-Wellesley Hospital, Newton, USA (GRID:grid.416176.3) (ISNI:0000 0000 9957 1751)
174 Université Libre de Bruxelles, Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)
175 Cliniques universitaires Saint-Luc, Department of Pathology, Brussels, Belgium (GRID:grid.48769.34) (ISNI:0000 0004 0461 6320)
176 Breast Center, Dept. OB&GYN and CCC (LMU), University of Munich, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
177 Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547)
178 University of Leuven, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
179 Université Libre de Bruxelles, Department of Pathology, Institut Jules Bordet, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)
180 German Breast Group GmbH, Neu-Isenburg, Germany (GRID:grid.434440.3) (ISNI:0000 0004 0457 2954)
181 Service de Biostatistique et d’Epidémiologie, Gustave Roussy, CESP, Université-Paris Sud, Université Paris-Saclay, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
182 Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France (GRID:grid.14925.3b)
183 Johanniter GmbH - Evangelisches Krankenhaus Bethesda Mönchengladbach, West German Study Group, Mönchengladbach, Germany (GRID:grid.476830.e)
184 Molecular Oncology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654)
185 University of Marburg, Department of Pathology, Marburg, Germany (GRID:grid.10253.35) (ISNI:0000 0004 1936 9756)
186 University of British Columbia, Department of Pathology and Laboratory Medicine, Columbia, USA (GRID:grid.417993.1)
187 St Vincent’s Hospital Melbourne, Department of Anatomical Pathology, Fitzroy, Australia (GRID:grid.413105.2) (ISNI:0000 0000 8606 2560)
188 Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)
189 University of Oxford, Clinical Trial Service Unit & Epidemiological Studies Unit, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
190 Fudan University Shanghai Cancer Center, Department of Pathology, Shanghai, China (GRID:grid.452404.3) (ISNI:0000 0004 1808 0942)
191 GZA-ZNA Hospitals, Department of Pathology, Antwerp, Belgium (GRID:grid.428965.4) (ISNI:0000 0004 7536 2436)
192 Odette Cancer Centre, Sunnybrook Research Institute, Department of Radiation Oncology, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
193 Oncology Merck & Co, New Jersey, USA (GRID:grid.17063.33)
194 The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Australian Clinical Labs, Darlinghurst, Australia (GRID:grid.415306.5) (ISNI:0000 0000 9983 6924)
195 Georgetown University Medical Center, Washington DC, USA (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438)
196 Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA (GRID:grid.414118.9) (ISNI:0000 0004 0464 4831)
197 Translational Medicine, Bristol-Myers Squibb, Princeton, USA (GRID:grid.419971.3)
198 Anatomic Pathology, Boston, USA (GRID:grid.21925.3d)
199 King’s College London, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); Guy’s Hospital, London, UK (GRID:grid.239826.4) (ISNI:0000 0004 0391 895X)
200 Peking University First Hospital Breast Disease Center, Beijing, China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621)
201 Peter MacCallum Cancer Centre, Department of Pathology, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
202 Dipartimento di Scienze della Salute (DSS), Firenze, Italy (GRID:grid.1055.1)
203 Department of Oncology, Champalimaud Clinical Centre, Lisbon, Portugal (GRID:grid.1055.1)
204 University of Melbourne, Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Victoria, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
205 Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, USA (GRID:grid.67033.31) (ISNI:0000 0000 8934 4045)
206 Department of Pathology, Fundación Valle del Lili, Cali, Colombia (GRID:grid.477264.4)
207 Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, USA (GRID:grid.240283.f) (ISNI:0000 0001 2152 0791)
208 University Hospital of Bellvitge, Oncobell, IDIBELL, L’Hospitalet del Llobregat, Department of Pathology, Barcelona, Spain (GRID:grid.240283.f)
209 Department of Development and Regeneration, Laboratory of Experimental Urology, KU Leuven, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
210 Department of Medical Oncology, Austin Health, Heidelberg, Australia (GRID:grid.410678.c)
211 Kansai Medical University to Tomoharu Sugie, Breast Surgery, Kansai Medical University Hospital, Department of Surgery, Hirakata, Japan (GRID:grid.410783.9) (ISNI:0000 0001 2172 5041)
212 Pathology Department, H.U. Vall d’Hebron, Barcelona, Spain (GRID:grid.23856.3a)
213 Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, Wuhan, USA (GRID:grid.417587.8) (ISNI:0000 0001 2243 3366)
214 Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Providence, USA (GRID:grid.17063.33)
215 Université Paris-Est, Créteil, France (GRID:grid.410511.0) (ISNI:0000 0001 2149 7878)
216 Praava Health, Dhaka, Bangladesh (GRID:grid.410511.0)